Catheter-related bloodstream infections Market: Epidemiology, Therapies, Companies, DelveInsight | Citius Pharmaceuticals, CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care

Catheter-related bloodstream infections therapies, such as DEFENCATH, MINO-LOK, and others, are expected to boost the Catheter-related bloodstream infections Market in the upcoming years.

DelveInsight has launched a new report on "Catheter-related bloodstream infections - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Catheter-related bloodstream infections, historical and forecasted epidemiology as well as the Catheter-related bloodstream infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Catheter-related bloodstream infections market report @ https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Catheter-related bloodstream infections Market Report:

As of May 2025, the FDA has approved DefenCath (taurolidine and heparin), the first and only antimicrobial catheter lock solution in the United States, to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in adult patients with kidney failure undergoing chronic hemodialysis through a central venous catheter.
Citius Pharmaceuticals has acquired the global rights to MINO-LOK from the University of Texas MD Anderson Cancer Center. The FDA has granted MINO-LOK both Qualified Infectious Disease Product (QIDP) and Fast Track Designation (FTD), with patent protection until 2024 and formulation patent protection through 2036.
In November 2023, CorMedix's DEFENCATH received FDA approval to treat catheter-related bloodstream infections (CRBSI) in adult kidney failure patients undergoing chronic hemodialysis through a central venous catheter. Gaining approval in Europe and Japan could further expand its market potential.
In May 2024, Citius Pharmaceuticals announced positive topline results from its pivotal Phase III clinical trial of MINO-LOK. The trial successfully met its primary endpoint, showing a statistically significant improvement in time to failure events in patients receiving MINO-LOK compared to those receiving a clinician-directed anti-infective lock solution.
The incidence, emergence speed, and clinical burden of CRBSIs are not fully understood. The pipeline for treating catheter-related bloodstream infections is limited, with Citius Pharmaceuticals being the sole developer of a treatment for these infections. An increase in CRBSI cases and the expected introduction of new therapies are anticipated to drive market growth in the coming years.
Key Catheter-related bloodstream infections companies such as Citius Pharmaceuticals, CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, and others are evaluating new drugs for Catheter-related bloodstream infections to improve the treatment landscape.
Promising Catheter-related bloodstream infections therapies include DEFENCATH, MINO-LOK, and others.

Catheter-related bloodstream infections Overview

Catheter-related bloodstream infection (CRBSI), also known as catheter-related sepsis, refers to the presence of bacteremia originating from an intravenous catheter. It is one of the most common, deadly, and expensive complications associated with central venous catheterization and is the leading cause of hospital-acquired bacteremia. CRBSI is caused by various organisms, including coagulase-negative staphylococci, Staphylococcus aureus, enteric gram-negative bacilli, enterococci, streptococci, pseudomonas, and others.

The diagnosis of CRBSI is often suspected in patients using a central venous catheter who present with fever or chills, unexplained hypotension, and no other obvious signs. Mild symptoms may include malaise and nausea, while more severe symptoms can include high fever with rigors, hypotension, vomiting, and altered mental status, despite a normal catheter exit site or tunnel upon physical examination.

The catheter-related bloodstream infection report provides an overview of CRBSI pathophysiology, diagnostic methods, and a detailed treatment algorithm, along with a real-world patient scenario tracing the journey from the initial symptom to diagnosis and the entire treatment process.

Catheter-related bloodstream infections Market Outlook

When a catheter-related bloodstream infection is suspected, the first recommendation from various guidelines is to remove the catheter. If the patient continues to have a fever, antibiotic and antifungal treatments are advised. Antibiotic therapy is often started empirically. Among the antibiotics commonly prescribed off-label for managing catheter-related bloodstream infections are daptomycin, vancomycin, cefazolin, ampicillin, ciprofloxacin, amikacin, and teicoplanin. Antifungals like fluconazole and amphotericin B are also used off-label for treatment. The therapeutic landscape for managing catheter-related bloodstream infections is evolving, though at a moderate pace, as only one pharmaceutical company is currently in late-stage development of a novel treatment for this condition.

Key companies, such as Citius Pharmaceuticals, are evaluating their lead candidates at various stages of clinical development with the goal of investigating their products as potential treatments for catheter-related bloodstream infections.

Discover how the Catheter-related bloodstream infections market is rising in the coming years @ https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Catheter Related Bloodstream Infection Marketed Drugs

DEFENCATH: CorMedix

Catheter-related bloodstream infections Emerging Drugs
MINO-LOK: Citius Pharmaceuticals

Scope of the Catheter-related bloodstream infections Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Catheter-related bloodstream infections Companies: Citius Pharmaceuticals, CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, and others
Key Catheter-related bloodstream infections Therapies: DEFENCATH, MINO-LOK, and others
Catheter-related bloodstream infections Therapeutic Assessment: Catheter-related bloodstream infections current marketed and Catheter-related bloodstream infections emerging therapies
Catheter-related bloodstream infections Market Dynamics: Catheter-related bloodstream infections market drivers and Catheter-related bloodstream infections market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Catheter-related bloodstream infections Unmet Needs, KOL's views, Analyst's views, Catheter-related bloodstream infections Market Access and Reimbursement

To know what's more in our Catheter-related bloodstream infections report, visit https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Catheter-related bloodstream infections Market Report:
Catheter-related bloodstream infections market report covers a descriptive overview and comprehensive insight of the Catheter-related bloodstream infections Epidemiology and Catheter-related bloodstream infections market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Catheter-related bloodstream infections market report provides insights into the current and emerging therapies.
The Catheter-related bloodstream infections market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Catheter-related bloodstream infections market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Catheter-related bloodstream infections market.

Got queries? Click here to know more about the Catheter-related bloodstream infections market Landscape https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Catheter-related bloodstream infections Patient Share (%) Overview at a Glance
5. Catheter-related bloodstream infections Market Overview at a Glance
6. Catheter-related bloodstream infections Disease Background and Overview
7. Catheter-related bloodstream infections Epidemiology and Patient Population
8. Country-Specific Patient Population of Catheter-related bloodstream infections
9. Catheter-related bloodstream infections Current Treatment and Medical Practices
10. Unmet Needs
11. Catheter-related bloodstream infections Emerging Therapies
12. Catheter-related bloodstream infections Market Outlook
13. Country-Wise Catheter-related bloodstream infections Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Catheter-related bloodstream infections Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Catheter-related bloodstream infections Market Outlook 2034 https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Catheter-related bloodstream infections Pipeline Insights, DelveInsight

"Catheter-related bloodstream infections Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Catheter-related bloodstream infections market. A detailed picture of the Catheter-related bloodstream infections pipeline landscape is provided, which includes the disease overview and Catheter-related bloodstream infections treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.